MicroBase Technology Valuation

Q: What is the Fair Price of 3184 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

3184 (NT$12.9) is trading above our estimate of [[fair value]] (NT$9.08)

Is 3184 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 3184 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 3184 (NT$12.9) is trading above our estimate of fair value (NT$9.08)

Significantly Below Fair Value: 3184 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 3184?

Key metric: As 3184 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 3184. This is calculated by dividing 3184's market cap by their current earnings.
What is 3184's PE Ratio?
PE Ratio	16.2x
Earnings	NT$64.11m
Market Cap	NT$1.04b

3184 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	4.1x
Enterprise Value/EBITDA	14.9x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 3184's PE Ratio compare to its peers?

The above table shows the PE ratio for 3184 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	62.7x
4744 CVC Technologies	99.8x	n/a	NT$1.1b
6730 Lagis Enterprise	16.7x	n/a	NT$1.2b
4161 Bioptik Technology Incorporation	17.4x	n/a	NT$1.7b
6493 Ttbio	117x	n/a	NT$502.6m
3184 MicroBase Technology	16.2x	n/a	NT$1.0b

Price-To-Earnings vs Peers: 3184 is good value based on its Price-To-Earnings Ratio (16.2x) compared to the peer average (62.7x).

Price to Earnings Ratio vs Industry

How does 3184's PE Ratio compare vs other companies in the TW Medical Equipment Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap

No more companies available in this PE range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 3184 is good value based on its Price-To-Earnings Ratio (16.2x) compared to the TW Medical Equipment industry average (19.6x).

Price to Earnings Ratio vs Fair Ratio

What is 3184's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

3184 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	16.2x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 3184's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Concord Medical

NT$866.7m

Provides hospital management support services in Taiwan, Myanmar, and China.

6518

NT$25.85

-3.7%

9.5%

Universal Vision Biotechnology

NT$18.0b

Operates a chain of eye care clinics in Taiwan and China.

3218

NT$214.50

1.4%

-27.4%

Pacific Hospital Supply

NT$6.4b

Manufactures, processes, and sells medical disposable products and equipment in Taiwan.

4126

NT$88.60

-0.3%

5.2%